文献速递肿瘤 PET/CT核素与放射性配体治疗

接受[177Lu]Lu-PSMA-617放射性配体治疗的mCRPC患者总病灶PSMA(TLP)变化可预测总生存:一项前瞻性登记研究的单中心评估

Change in total lesion PSMA (TLP) during [177Lu]Lu-PSMA-617 radioligand therapy predicts overall survival in patients with mCRPC: monocentric evaluation of a prospective registry.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-10-27

本研究基于前瞻性登记研究(NCT04833517),纳入102例转移性去势抵抗性前列腺癌(mCRPC)患者,在基线及两周期PSMA放射性配体治疗后行[68Ga]Ga-PSMA-11 PET/CT,以半自动肿瘤分割测量全身参数总病灶PSMA(TLP)。采用Kaplan-Meier法确定ΔTLP阈值-30%/+30%可将患者分为部分缓解(PR)、疾病稳定(SD)和疾病进展(PD),三组间总生存(OS)差异有统计学意义;而新发转移灶作为独立标准或联合TLP、以及PSA血清值变化均未能显著区分SD与PD。

要点

  • ΔTLP阈值-30%/+30%可显著区分PR、SD与PD三组的总生存(PR/PD p=0.001;PR/SD p=0.001;SD/PD p=0.018)。
  • 将新发转移灶作为PD独立标准时,SD与PD的OS无显著差异(p=0.455),联合TLP时亦无显著差异(p=0.191)。
  • PSA血清值变化未能显著区分SD与PD(p=0.973)。

核心结论

  • 在迄今最大规模的单中心研究中,TLP被证明是一种合格的预后生物标志物,采用ΔTLP阈值-30%/+30%。
  • TLP可显著区分PR、SD与PD,而其他反应标准未能区分SD与PD。
  • 使用TLP时,新发转移灶的出现并非预测OS的必需信息。

研究设计与样本

  • 本研究为前瞻性登记研究(NCT04833517)的单中心评估。
  • 共纳入102例mCRPC患者,在基线及两周期PSMA-RLT后接受[68Ga]Ga-PSMA-11 PET/CT。
  • TLP通过半自动肿瘤分割测量,定义为所有肿瘤病灶体积与摄取乘积之和(∑ Volume × SUVmean)。
  • 采用Kaplan-Meier法确定ΔTLP阈值以分类PR、SD和PD并评估总生存。

主要发现

  • 对于ΔTLP阈值-30%/+30%(以及更高阈值-40%/+40%或-50%/+50%),三个反应类别之间均出现显著差异(PR/PD:p=0.001;PR/SD:p=0.001;SD/PD:p=0.018)。
  • 将新发转移灶作为PD独立标准时,SD与PD的OS无显著差异(p=0.455);与TLP联合应用时亦无显著差异(p=0.191)。
  • PSA血清值变化未能显著区分SD与PD(p=0.973)。

关键数值与推荐

  • ΔTLP阈值-30%/+30%用于分类PR、SD和PD,三组间OS差异有统计学意义(PR/PD p=0.001;PR/SD p=0.001;SD/PD p=0.018)。
  • 新发转移灶作为PD独立标准时,SD与PD的OS无显著差异(p=0.455)。
  • 新发转移灶联合TLP时,SD与PD的OS无显著差异(p=0.191)。
  • PSA血清值变化未能显著区分SD与PD(p=0.973)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study investigates imaging response of [177Lu]Lu-PSMA-617 radioligand therapy (RLT) based on the whole-body parameter total lesion PSMA (TLP), derived by PSMA-PET/CT and reflecting the total tumor burden, in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in a prospective registry (NCT04833517). METHODS: A total of n = 102 mCRPC patients received a [68Ga]Ga-PSMA-11 PET/CT at baseline and after two cycles of PSMA-RLT, in which TLP was measured by using a semi-automated tumor segmentation. TLP was defined as the summed products of volume and uptake (∑ Volume × SUVmean) of all tumor lesions. The Kaplan-Meier method was used to determine the most appropriate ∆TLP thresholds for classification into partial remission (PR), stable disease (SD), and progressive disease (PD) regarding overall survival (OS). Furthermore, we analyzed criteria that are also frequently used in established response frameworks, such as the occurrence of new metastases as independent criterion (I) or in combination with change in tumor burden (II), and the change in PSA serum value (III). RESULTS: For the ∆TLP thresholds -30%/+30% (and also for higher thresholds, -40%/+40% or -50%/+50%), significant differences between all three response categories became apparent (PR/PD: p = 0.001; PR/SD: p = 0.001; SD/PD: p = 0.018). Including the development of new metastases as independent criterion of PD, there was no significant difference in OS between SD and PD (p = 0.455), neither when applied in combination with TLP (p = 0.191). Similarly, significant differentiation between SD and PD was not achieved by PSA serum value (p = 0.973). CONCLUSION: In the largest monocentric study to date, TLP is shown to be a qualified prognostic biomarker, applying ∆TLP thresholds of -30%/+30%. It significantly differentiated between PR, SD, and PD, whereas other response criteria did not differentiate SD vs. PD. Using TLP, the development of new metastases is not a required information for predicting OS.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Burgard C, Hein C, Blickle A, et al. Change in total lesion PSMA (TLP) during [177Lu]Lu-PSMA-617 radioligand therapy predicts overall survival in patients with mCRPC: monocentric evaluation of a prospective registry. Eur J Nucl Med Mol Imaging. 2023. PMID: 37889298. doi:10.1007/s00259-023-06476-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。